Dr. Weiwei Xiao 肖巍魏
Chief Physician
Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive treatment for gastrointestinal tumors, including rectal, colon, anal canal, pancreatic, gastric, liver, gallbladder, bile duct cancers, and melanoma. Expertise in sphincter-preserving therapy for low rectal cancer and combined therapy for anal squamous cell carcinoma.
Dr. Xiao holds a PhD in Oncology and serves as a Chief Physician and Master’s supervisor. Research focuses on radiation therapy for gastrointestinal tumors, with findings cited in the 2018 NCCN Rectal Cancer Guidelines. Dr. Xiao has led multiple clinical studies on colorectal cancer and secured funding from the National Natural Science Foundation of China.
Professional roles
- Member, Multidisciplinary Treatment (MDT) Committee, Colorectal Tumor Professional Committee, Chinese Medical Doctor Association
- Member, Youth Committee, Colorectal Tumor Professional Committee, Chinese Medical Doctor Association
- Vice Chair, Youth Committee, Radiotherapy Professional Committee, Guangdong Anti-Cancer Association
- Vice Chair, First Youth Committee, Pediatric Branch, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Xiao Weiwei). Papers usually list the name as Weiwei Xiao or Xiao W.
Selected publications
99 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Dis Colon Rectum, 2026 (senior author): Building Machine Learning Models Based on Oxidative Stress Index Score to Predict Survival of Locally Advanced Rectal Cancer Receiving Different Neoadjuvant Therapy Patterns. PubMed 42583907
- MedComm (2020), 2026 (senior author): Safety and Efficacy of a Sandwich Total Neoadjuvant Therapy Strategy for Low-Risk Distal Locally Advanced Rectal Cancer: Results From the TESS Phase II Trial. PubMed 42318526
- Cancer Cell, 2024 (first author): Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. PubMed 39094560
- Ther Adv Med Oncol, 2024 (senior author): Distinct clinical characteristics in stage III rectal cancer among different age groups and treatment outcomes after neoadjuvant chemoradiotherapy. PubMed 38347922
- Cancer Med, 2023 (senior author): Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. PubMed 37156624
- Front Immunol, 2023 (first author): Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer. PubMed 37033988
- Front Med (Lausanne), 2022 (senior author): A nomogram for predicting 10-year cancer specific survival in patients with pathological T3N0M0 rectal cancer. PubMed 36072948
- Cancer Med, 2022 (senior author): Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China. PubMed 34816622
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion